Drug intelligence / Profile preview

TSHA-121

Development stage: Unknown
Lead developer: Taysha Gene Therapies
Modality: Gene Therapies

Overview

TSHA-121 is a gene therapy investigational drug developed using adeno-associated virus (AAV) vector technology, indicated for the treatment of neurological disorders[5]. Specific disease indications, mechanism of action, and agent composition have not been disclosed in publicly available sources[5][7]. TSHA-121 was initially developed by The University of Texas Southwestern Medical Center and its most advanced R&D status is preclinical or early-phase clinical investigation[5].

Brand names: TSHA-121TSHA121TSHA 121
Other names: TSHA-121TSHA121TSHA 121

Beyond the preview

Go deeper on TSHA-121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSHA-121.

Explore the full profile